Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15565304 | 0.82 | L3MBTL1 (0.48) | L3MBTL1LMNAMAPTTP53ALDH1A1 | |
| SCHEMBL22893643 | 0.80 | OPRM1 (0.51) | L3MBTL1LMNAMAPTTP53ALDH1A1 | |
| SCHEMBL16118741 | 0.75 | TSHR (0.48) | L3MBTL1HPGDPKMNPSR1LMNA | |
| SCHEMBL16118742 | 0.75 | TSHR (0.48) | L3MBTL1HPGDPKMNPSR1LMNA | |
| SCHEMBL18317080 | 0.75 | TSHR (0.48) | L3MBTL1HPGDPKMNPSR1LMNA | |
| SCHEMBL20487581 | 0.74 | JAK2 (0.46) | L3MBTL1ALDH1A1POLB | |
| SCHEMBL20488330 | 0.74 | JAK2 (0.46) | L3MBTL1ALDH1A1POLB | |
| SCHEMBL850188 | 0.72 | FABP7 (0.50) | L3MBTL1HPGDPKMLMNAMAPK1 | |
| SCHEMBL280126 | 0.71 | FABP7 (0.58) | L3MBTL1HPGDPKMLMNAMAPK1 | |
| SCHEMBL10917021 | 0.71 | FABP7 (0.58) | L3MBTL1HPGDPKMLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20210284640-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Lazuli, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-11046685-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3760202-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Morphic Therapeutic, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| WO-2018160522-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Lazuli, Inc. (US) | 2018-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046685-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | L3MBTL1 1323/4885HPGD 3488/4885PKM 4150/4885 |
| US-20210284640-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | L3MBTL1 1149/4885HPGD 3105/4885PKM 4266/4885 |
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | L3MBTL1 1156/4885HPGD 3468/4885PKM 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.